Outcomes of controlled human malaria infection after BCG vaccination.
Adolescent
Adult
Animals
Anopheles
/ parasitology
B7-2 Antigen
/ metabolism
BCG Vaccine
/ administration & dosage
C-Reactive Protein
/ metabolism
Cytokines
/ blood
Female
GPI-Linked Proteins
/ metabolism
Granzymes
/ blood
HLA-DR Antigens
/ metabolism
Humans
Immunity, Innate
/ immunology
Immunologic Memory
/ immunology
Interferon-gamma
/ blood
Killer Cells, Natural
/ immunology
Lymphocyte Activation
/ immunology
Malaria, Falciparum
/ immunology
Male
Parasitemia
/ prevention & control
Plasmodium falciparum
/ immunology
Receptors, IgG
/ metabolism
Vaccination
Young Adult
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
20 02 2019
20 02 2019
Historique:
received:
29
01
2018
accepted:
20
01
2019
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
4
4
2019
Statut:
epublish
Résumé
Recent evidence suggests that certain vaccines, including Bacillus-Calmette Guérin (BCG), can induce changes in the innate immune system with non-specific memory characteristics, termed 'trained immunity'. Here we present the results of a randomised, controlled phase 1 clinical trial in 20 healthy male and female volunteers to evaluate the induction of immunity and protective efficacy of the anti-tuberculosis BCG vaccine against a controlled human malaria infection. After malaria challenge infection, BCG vaccinated volunteers present with earlier and more severe clinical adverse events, and have significantly earlier expression of NK cell activation markers and a trend towards earlier phenotypic monocyte activation. Furthermore, parasitemia in BCG vaccinated volunteers is inversely correlated with increased phenotypic NK cell and monocyte activation. The combined data demonstrate that BCG vaccination alters the clinical and immunological response to malaria, and form an impetus to further explore its potential in strategies for clinical malaria vaccine development.
Identifiants
pubmed: 30787276
doi: 10.1038/s41467-019-08659-3
pii: 10.1038/s41467-019-08659-3
pmc: PMC6382772
doi:
Substances chimiques
B7-2 Antigen
0
BCG Vaccine
0
CD86 protein, human
0
Cytokines
0
FCGR3B protein, human
0
GPI-Linked Proteins
0
HLA-DR Antigens
0
IFNG protein, human
0
Receptors, IgG
0
Interferon-gamma
82115-62-6
C-Reactive Protein
9007-41-4
Granzymes
EC 3.4.21.-
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
874Subventions
Organisme : European Research Council
ID : 310372
Pays : International
Références
J Immunol. 2006 Oct 15;177(8):5736-45
pubmed: 17015763
J Infect Dis. 2014 Dec 15;210(12):1981-90
pubmed: 24970846
J Innate Immun. 2014;6(2):152-8
pubmed: 24192057
Int J Epidemiol. 2005 Jun;34(3):540-7
pubmed: 15659474
J Infect Dis. 2011 Jul 15;204(2):245-52
pubmed: 21673035
Clin Infect Dis. 2017 Oct 1;65(7):1183-1190
pubmed: 29579158
Infect Immun. 1981 Jul;33(1):199-211
pubmed: 7021424
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
Nat Med. 2014 Jan;20(1):47-53
pubmed: 24362933
Cell Host Microbe. 2012 Aug 16;12(2):223-32
pubmed: 22901542
J Infect Dis. 2015 Dec 15;212(12):1930-8
pubmed: 26071565
Clin Immunol. 2014 Dec;155(2):213-9
pubmed: 25451159
Mol Biochem Parasitol. 2001 Dec;118(2):247-51
pubmed: 11738714
J Infect Dis. 1997 Apr;175(4):915-20
pubmed: 9086149
BMJ. 2010 Mar 15;340:c671
pubmed: 20231251
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
Cell Rep. 2014 Apr 24;7(2):436-447
pubmed: 24703850
Malar J. 2016 Aug 05;15(1):398
pubmed: 27495296
Nat Immunol. 2015 Jul;16(7):675-9
pubmed: 26086132
Science. 2014 Sep 26;345(6204):1251086
pubmed: 25258085
Clin Exp Immunol. 2003 Jun;132(3):467-72
pubmed: 12780694
Nature. 1976 Jan 29;259(5541):309-11
pubmed: 765838
Eur J Immunol. 2010 Dec;40(12):3472-7
pubmed: 21072880
Infect Immun. 2015 Sep;83(9):3732-9
pubmed: 26169270
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
J Immunol. 2003 Nov 15;171(10):5396-405
pubmed: 14607943
Parasite Immunol. 1988 Jan;10(1):17-31
pubmed: 3281101
Semin Immunol. 2018 Oct;39:35-43
pubmed: 30007489
PLoS Pathog. 2014 Oct 30;10(10):e1004485
pubmed: 25356988
N Engl J Med. 2016 Jun 30;374(26):2519-29
pubmed: 27355532
Vaccine. 2000 Nov 22;19(7-8):779-87
pubmed: 11115699
PLoS One. 2012;7(6):e38434
pubmed: 22701640
J Clin Invest. 1992 Aug;90(2):515-23
pubmed: 1644922
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7
pubmed: 23599283
Semin Immunol. 2014 Dec;26(6):512-7
pubmed: 25444548
PLoS One. 2013 Jul 04;8(7):e66115
pubmed: 23861742
Expert Rev Vaccines. 2006 Apr;5(2):277-93
pubmed: 16608427
PLoS One. 2015 May 01;10(5):e0124243
pubmed: 25933168
Trop Med Int Health. 2007 Feb;12(2):224-9
pubmed: 17300629
EBioMedicine. 2016 Aug;10:312-7
pubmed: 27498365